| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA3592345 | B | Inhibition of human recombinant BACE1 using Mca-SEVNLDAEFK-DNP substrate assessed as substrate hydrolysis after 2 hrs by HPLC-FLU analysis | Homo sapiens | 5 | ALA3588858 | single protein format | Scientific Literature | |
| 2. | ALA3592346 | B | Apparent inhibition of human recombinant BACE2 using Mca-SEVNLDAEFK-DNP substrate assessed as substrate hydrolysis after 1 hr by HPLC-FLU analysis | Homo sapiens | 5 | ALA3588858 | single protein format | Scientific Literature | |
| 3. | ALA3592347 | B | Selectivity ratio of Ki(app) for human recombinant BACE2 to Ki for human recombinant BACE1 | Homo sapiens | 5 | ALA3588858 | assay format | Scientific Literature | |
| 4. | ALA3592348 | A | Half life in human serum by HPLC-FLU analysis | Homo sapiens | 4 | ALA3588858 | cell-free format | Scientific Literature | |
| 5. | ALA3592349 | A | Half life in mouse brain by HPLC-FLU analysis | Mus musculus | 4 | ALA3588858 | tissue-based format | Scientific Literature | |
| 6. | ALA3592353 | A | Retention time of the compound in female mouse brain treated with 0.53 mg/kg, iv (3S,6S,9S,12S,15S,18S,21R,23S,24S,27S,30S,33S)-33-acetamido-15-benzyl-3-carbamoyl-6-(2-carboxyethyl)-27-(carboxymethyl)-23-hydroxy-12-(4-hydroxybenzyl)-24,30-diisobutyl-18-isopropyl-9,21-dimethyl-5,8,11,14,17,20,26,29,32-nonaoxo-4,7,10,13,16,19,25,28,31-nonaazahexatriacontane-1,36-dioic acid by HPLC-FLU analysis | Mus musculus | 1 | ALA3588858 | organism-based format | Scientific Literature | |
| 7. | ALA3592354 | A | Drug formation in female mouse brain treated with 0.53 mg/kg, iv (3S,6S,9S,12S,15S,18S,21R,23S,24S,27S,30S,33S)-33-acetamido-15-benzyl-3-carbamoyl-6-(2-carboxyethyl)-27-(carboxymethyl)-23-hydroxy-12-(4-hydroxybenzyl)-24,30-diisobutyl-18-isopropyl-9,21-dimethyl-5,8,11,14,17,20,26,29,32-nonaoxo-4,7,10,13,16,19,25,28,31-nonaazahexatriacontane-1,36-dioic acid measured up to 2 hrs by HPLC-FLU/LC-MS analysis | Mus musculus | 1 | ALA3588858 | organism-based format | Scientific Literature | |
| 8. | ALA3592355 | A | Drug formation in Wistar rat serum treated with 0.53 mg/kg, iv (3S,6S,9S,12S,15S,18S,21R,23S,24S,27S,30S,33S)-33-acetamido-15-benzyl-3-carbamoyl-6-(2-carboxyethyl)-27-(carboxymethyl)-23-hydroxy-12-(4-hydroxybenzyl)-24,30-diisobutyl-18-isopropyl-9,21-dimethyl-5,8,11,14,17,20,26,29,32-nonaoxo-4,7,10,13,16,19,25,28,31-nonaazahexatriacontane-1,36-dioic acid measured after 2 hrs by HPLC-FLU/LC-MS analysis | Rattus norvegicus | 1 | ALA3588858 | organism-based format | Scientific Literature | |
| 9. | ALA3592356 | A | Drug uptake in female mouse brain at 0.53 mg/kg, iv up to 1 hr by HPLC-FLU analysis | Mus musculus | 1 | ALA3588858 | organism-based format | Scientific Literature | |
| 10. | ALA3592362 | A | Drug formation in Wistar rat brain cortex treated with 0.53 mg/kg, iv (3S,6S,9S,12S,15S,18S,21R,23S,24S,27S,30S,33S)-33-acetamido-15-benzyl-3-carbamoyl-6-(2-carboxyethyl)-27-(carboxymethyl)-23-hydroxy-12-(4-hydroxybenzyl)-24,30-diisobutyl-18-isopropyl-9,21-dimethyl-5,8,11,14,17,20,26,29,32-nonaoxo-4,7,10,13,16,19,25,28,31-nonaazahexatriacontane-1,36-dioic acid measured after 2 hrs by HPLC-FLU/LC-MS analysis | Rattus norvegicus | 1 | ALA3588858 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!